Mr. Rose is the CEO of Endovascular Engineering, a Menlo Park-based company focused on the treatment of venous thromboembolism. Previously, Mr. Rose served as CEO of LimFlow S.A., a pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). He joined LimFlow as the first employee and successfully guided the company through its acquisition by Inari Medical, Inc. He assembled a world-class team that developed and commercialized a practice-changing therapy for the treatment of late-stage CLTI, which resulted in an FDA approval and a landmark publication in the New England Journal of Medicine. Previously, Mr. Rose served as Vice President and General Manager Europe for Direct Flow Medical, and led commercial and clinical activities at Sequana Medical AG. Earlier in his career, he held successive commercial leadership roles at Medtronic in Europe and began his medtech career in early-stage venture capital in London. Mr. Rose has a BA and MA from the University of Virginia and an MBA from its Darden School of Business.